Literature DB >> 9085307

Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy.

Michael L Nichols1, Yvan Lopez, Michael H Ossipov, Di Bian, Frank Porreca.   

Abstract

Neuropathic pains arising from peripheral nerve injury can result in increased sensitivity to both noxious and non-noxious stimuli and are accompanied by a number of neuroplastic alterations at the level of the spinal cord including upregulation of neurotransmitters including dynorphin, cholecystokinin and neuropeptide Y. Additionally, such pain states appear to be associated with activation of excitatory amino acid receptors including the N-methyl-D-aspartate (NMDA) receptor. Neuropathic pains have often been classified as 'opioid resistant' in both clinical and laboratory settings. As it is known that dynorphin produces 'non-opioid' effects through interaction with NMDA receptors and this peptide is upregulated after peripheral nerve injury, the present studies were undertaken to determine the possible importance of this substance in the neuropathic state. Nerve injury was produced in rats by tight ligation of the L5 and L6 spinal roots of the sciatic nerve. Catheters were inserted for the intrathecal (i.t.) delivery of drug to the lumbar spinal cord. Tactile allodynia was determined by measuring responses to probing the plantar surface of the affected limb with von Frey filaments, and acute nociception was determined in the 55 degrees C hot-water tail-flick test in nerve-ligated and sham-operated subjects. Intrathecal administration of MK-801 or antisera to dynorphin A (1-13) did not alter the tactile allodynia associated with nerve-ligation injury or the baseline tail-flick latency in either sham-operated or nerve-injured animals. As previously reported, i.t. morphine did not alter tactile allodynia and showed reduced potency and efficacy to block the tail-flick reflex in nerve-injured animals. Co-administration, however, of i.t. morphine with MK-801, or i.t. antisera to dynorphin A (1-13) given prior to morphine elicited both a full antiallodynic response and a complete block of the tail-flick reflex in nerve-injured animals. These results suggest that tonic activation of NMDA receptors, following peripheral nerve injury, is involved with the attenuation of the effectiveness of spinal morphine in a model of neuropathic pain. Additionally, this tonic NMDA activity may be mediated, in part, by increased levels of endogenous dynorphin associated with peripheral nerve injury.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085307     DOI: 10.1016/S0304-3959(96)03282-4

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  23 in total

1.  Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain.

Authors:  M J Schwei; P Honore; S D Rogers; J L Salak-Johnson; M P Finke; M L Ramnaraine; D R Clohisy; P W Mantyh
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

Review 2.  Pathobiology of dynorphins in trauma and disease.

Authors:  Kurt F Hauser; Jane V Aldrich; Kevin J Anderson; Georgy Bakalkin; MacDonald J Christie; Edward D Hall; Pamela E Knapp; Stephen W Scheff; Indrapal N Singh; Bryce Vissel; Amina S Woods; Tatiana Yakovleva; Toni S Shippenberg
Journal:  Front Biosci       Date:  2005-01-01

3.  Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats.

Authors:  C Courteix; M A Coudoré-Civiale; A M Privat; J M Zajac; A Eschalier; J Fialip
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

4.  Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Authors:  T W Vanderah; L R Gardell; S E Burgess; M Ibrahim; A Dogrul; C M Zhong; E T Zhang; T P Malan; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

Review 5.  Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?

Authors:  Z Wiesenfeld-Hallin
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

6.  Spinal astrocytes produce and secrete dynorphin neuropeptides.

Authors:  Andrew Wahlert; Lydiane Funkelstein; Bethany Fitzsimmons; Tony Yaksh; Vivian Hook
Journal:  Neuropeptides       Date:  2013-01-03       Impact factor: 3.286

7.  Effect of naltrexone on neuropathic pain in mice locally transfected with the mutant μ-opioid receptor gene in spinal cord.

Authors:  Jen-Hsin Kao; Man-Jun Gao; Pao-Pao Yang; Ping-Yee Law; Horace H Loh; Pao-Luh Tao
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

Review 8.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

Review 9.  Importance of sex to pain and its amelioration; relevance of spinal estrogens and its membrane receptors.

Authors:  Alan R Gintzler; Nai-Jiang Liu
Journal:  Front Neuroendocrinol       Date:  2012-10-02       Impact factor: 8.606

10.  Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists.

Authors:  Taline V Khroyan; Willma E Polgar; Juan Orduna; Faming Jiang; Cris Olsen; Lawrence Toll; Nurulain T Zaveri
Journal:  Eur J Pharmacol       Date:  2009-03-12       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.